Nymox Pharmaceutical Corporation
Nymox Pharmaceutical Corporation (NYMXF) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
nymxf · pe ratio · data through Jun 9, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMInsufficient PE history data (fewer than 3 valid fiscal years).
PE Ratio vs Peers
Biotechnology · 5 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Nymox Pharmaceutical CorporationYou NYMXF | $9M | N/A | — | — |
 Devonian Health Group Inc. DVHGF | $30M | N/A | — | -$1.76 |
 Hemostemix Inc. HMTXF | $8M | N/A | — | -$0.03 |
 HOOKIPA Pharma Inc. HOOK | $14M | N/A | — | -$1.09 |
 EOM Pharmaceuticals Holdings, Inc. IMUC | $31M | N/A | — | -$0.02 |
 Inhibitor Therapeutics, Inc. INTI | $15M | N/A | — | -$0.02 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Nymox Pharmaceutical Corporation (NYMXF) measures how much investors pay for each dollar of the company's trailing earnings. NYMXF's current PE ratio of N/A is calculated by dividing its stock price of $0.09 by its TTM earnings per share of —.
Frequently asked questions
NYMXF pe ratio · 6 questionsNYMXF's current PE ratio is N/A as of 2026-06-09, based on a stock price of $0.09 and TTM EPS of —. Data sourced from Financial Modeling Prep via NYMXF's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Nymox Pharmaceutical Corporation SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09